Puma Biotech (PBYI) Reports Q4 EPS of $0.01

Puma Biotech (NASDAQ: PBYI) reported Q4 EPS of $0.01, versus ($0.32) reported last year. Revenue for the quarter came in at $58.7 million versus the consensus estimate of $59.96 million.

For earnings history and earnings-related data on Puma Biotech (PBYI) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Redburn upgrades Southwest, stays bullish on Delta and United
• Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer